Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial
-
Published:2024-09
Issue:
Volume:195
Page:107901
-
ISSN:0169-5002
-
Container-title:Lung Cancer
-
language:en
-
Short-container-title:Lung Cancer
Author:
Lu ShunORCID, Zhang Yiping, Zhang Guojun, Zhou Jianying, Cang Shundong, Cheng YingORCID, Wu Gang, Cao Peiguo, Lv Dongqing, Jian Hong, Jin Xiangming, Chen Chengshui, Tian Panwen, Wang Kai, Jiang Guanming, Chen Gongyan, Chen Qun, Zhao Hui, Ding Cuimin, Guo Renhua, Sun Guoping, Wang Bin, Jiang LiyanORCID, Liu ZheORCID, Fang Jian, Yang Junquan, Zhuang Wu, Liu Yunpeng, Zhang Jian, Pan Yueyin, Chen Jun, Yu Qitao, Zhao Min, Cui Jiuwei, Li Dianming, Yi Tienan, Yu Zhuang, Yang Yan, Zhang Yan, Zhi Xiuyi, Huang Yunchao, Wu Rong, Chen Liangan, Zang Aimin, Cao Lejie, Li Qingshan, Li Xiaoling, Song Yong, Wang Donglin, Zhang Shucai, Ding Lieming, Zhang Ling, Ji Dong, Shen Zhilin
Reference30 articles.
1. Zhang SS, Ou SI. Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?. Lung Cancer (Auckl). 2022;13:67-73. 2. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer;Mok;N. Engl. J. Med.,2017 3. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N. Engl. J. Med.,2018 4. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N. Engl. J. Med.,2020 5. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study;Shi;Lancet Respir. Med.,2021
|
|